CD163 and neoplasm: Immunohistochemistry for CD68 (a pan-macrophage marker) and CD163 (a specific M2 macrophage marker, M2 macrophages are thought to facilitate tumor growth) was comparable between patients <40 years, 40–65 years, and >65 years.